CloneID: H3
Antigen Long Description: H3 was selected by its affinity for GST-LMP1 from a human phage display library after 4 rounds of panning.
Origin Pub PMID: 17460414
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: P03230
Specificity Statement: H3 scFv is specific to the LMP1 C terminal region where it binds to CTAR-1 (GST-LMP1[187-242]). LMP1 is expessed constitutively in many EBV-associated tumours and this protein can cause B lymphocyte and rodent fibroblast transformation, cell apoptosis inhibition by up-regulation of anti-apoptotic proteins, cell surface marker and DNA methyltransferase activty up-regulation, and cell adhesion molecule and cyclin-dependent kinase downregulation. The C-terminal domain of LMP1 is made up of 3 C-terminal activating regions (CTARs) which interact with TNF receptor-associated proteins and TNF receptor-associated death domain protein, which medite activation of NF-kB and AP-1. A LMP1 TAR is also involved in the JAK/STAT pathway.
Application Notes (Clone): H3 scFv can reduce LMP1-mediated NF-kappaB activation in HEK293 cells by ~50% as well as inhibit LMP1 functions in epithelial cells - enables the potential use of H3 for attenuating the LMP1 function in LMP1-positive tumors. H3 is also capable of reducing the trans-membrane migration ability of MDCK-LMP1 cells by blocking the CTAR-mediated signaling pathway. H3 can also be used to pull down LMP1 in IPs, and can be used for ELISAs and to visualise LMP1 distibution in IF studies.